BioCentury | Feb 16, 2012
Distillery Therapeutics

Indication: Cancer

...L-Nutra Inc. on chemotherapy efficacy and seeing if fasting can decrease the number of side effects. L-Nutra...
...findings. SciBX 5(7); doi:10.1038/scibx.2012.173 Published online Feb. 16, 2012 Patent applications filed; exclusively licensed to L-Nutra...
BioCentury | Feb 15, 2010
Company News

Nutra Pharma management update

Nutra Pharma Corp. (OTCBB:NPHC), Boca Raton, Fla. Business: Neurology, Diagnostic Hired: David Isserman as CMO, formerly a company consultant WIR Staff Diagnostic Neurology...
BioCentury | Jun 15, 2009
Clinical News

Nutra Pharma preclinical data

Data published in Toxicon showed that RPI-78 significantly and dose-dependently inhibited the electrical activity of thalamic parafascicular nucleus (Pf) pain-processing neurons in rats for at least 2 hours compared with less than 30 minutes for...
BioCentury | Feb 23, 2009
Clinical News

Nutra Pharma preclinical data

Data from a rat model of arthritis showed that RPI-78 (cobratoxin) reduced paw swelling and mechanical and thermal hyperalgesia. Treatment also reduced the production of tumor necrosis factor (TNF) alpha , IL-1 and IL-2 and increased...
BioCentury | Nov 24, 2008
Company News

Nutra Pharma sales and marketing update

Nutra's drug discovery subsidiary, ReceptoPharm Inc., will provide its RPI-78M under a compassionate use program to patients who were enrolled in a completed Phase IIb/IIIa trial to treat adrenomyeloneuropathy (AMN). Data from the trial are...
BioCentury | Apr 21, 2008
Company News

Nutra Pharma, ReceptoPharm Inc. deal

In 2006, the companies signed a letter of intent for Nutra Pharma to acquire the 61.9% of ReceptoPharm it did not already own for $2.4 million in stock but were unable to close the deal...
BioCentury | Jan 7, 2008
Company News

NanoLogix, Nutra Pharma deal

The companies expanded a license to give Nutra Pharma rights to NanoLogix's IP covering the detection of non-tuberculosis mycobacteria in the environment. Nutra Pharma previously had rights to test patients. Nutra Pharma's Designer Diagnostics Inc....
BioCentury | Aug 13, 2007
Clinical News

Nutra Pharma preclinical data

In mice and rats, subcutaneous injections of RPI-78 blocked pain signals as effectively as morphine. NPHC said the cobratoxin had a longer duration of effect compared with morphine. Nutra Pharma Corp. (NPHC), Boynton Beach, Fla....
BioCentury | Jul 16, 2007
Clinical News

RPI-78M: Completed Phase IIb enrollment

NPHC's ReceptoPharm Inc. subsidiary completed enrollment of 16 patients in a placebo-controlled, U.K. Phase IIb trial of oral RPI-78M. Nutra Pharma Corp. (NPHC), Boynton Beach, Fla. Product: RPI-78M Business: Neurology Molecular target: NA Description: Modified...
BioCentury | Mar 12, 2007
Company News

Nutra Pharma, Zhong Xin Dong Tai Co. Ltd. deal

NPHC's ReceptoPharm Inc. division and Zhong Xin signed a nonbinding letter of intent to create a JV to develop and market NPHC's RPI-MN antiviral compound in China. Zhong Xin's Nanogene Biotechnology Co. Ltd. subsidiary will...
Items per page:
1 - 10 of 30
BioCentury | Feb 16, 2012
Distillery Therapeutics

Indication: Cancer

...L-Nutra Inc. on chemotherapy efficacy and seeing if fasting can decrease the number of side effects. L-Nutra...
...findings. SciBX 5(7); doi:10.1038/scibx.2012.173 Published online Feb. 16, 2012 Patent applications filed; exclusively licensed to L-Nutra...
BioCentury | Feb 15, 2010
Company News

Nutra Pharma management update

Nutra Pharma Corp. (OTCBB:NPHC), Boca Raton, Fla. Business: Neurology, Diagnostic Hired: David Isserman as CMO, formerly a company consultant WIR Staff Diagnostic Neurology...
BioCentury | Jun 15, 2009
Clinical News

Nutra Pharma preclinical data

Data published in Toxicon showed that RPI-78 significantly and dose-dependently inhibited the electrical activity of thalamic parafascicular nucleus (Pf) pain-processing neurons in rats for at least 2 hours compared with less than 30 minutes for...
BioCentury | Feb 23, 2009
Clinical News

Nutra Pharma preclinical data

Data from a rat model of arthritis showed that RPI-78 (cobratoxin) reduced paw swelling and mechanical and thermal hyperalgesia. Treatment also reduced the production of tumor necrosis factor (TNF) alpha , IL-1 and IL-2 and increased...
BioCentury | Nov 24, 2008
Company News

Nutra Pharma sales and marketing update

Nutra's drug discovery subsidiary, ReceptoPharm Inc., will provide its RPI-78M under a compassionate use program to patients who were enrolled in a completed Phase IIb/IIIa trial to treat adrenomyeloneuropathy (AMN). Data from the trial are...
BioCentury | Apr 21, 2008
Company News

Nutra Pharma, ReceptoPharm Inc. deal

In 2006, the companies signed a letter of intent for Nutra Pharma to acquire the 61.9% of ReceptoPharm it did not already own for $2.4 million in stock but were unable to close the deal...
BioCentury | Jan 7, 2008
Company News

NanoLogix, Nutra Pharma deal

The companies expanded a license to give Nutra Pharma rights to NanoLogix's IP covering the detection of non-tuberculosis mycobacteria in the environment. Nutra Pharma previously had rights to test patients. Nutra Pharma's Designer Diagnostics Inc....
BioCentury | Aug 13, 2007
Clinical News

Nutra Pharma preclinical data

In mice and rats, subcutaneous injections of RPI-78 blocked pain signals as effectively as morphine. NPHC said the cobratoxin had a longer duration of effect compared with morphine. Nutra Pharma Corp. (NPHC), Boynton Beach, Fla....
BioCentury | Jul 16, 2007
Clinical News

RPI-78M: Completed Phase IIb enrollment

NPHC's ReceptoPharm Inc. subsidiary completed enrollment of 16 patients in a placebo-controlled, U.K. Phase IIb trial of oral RPI-78M. Nutra Pharma Corp. (NPHC), Boynton Beach, Fla. Product: RPI-78M Business: Neurology Molecular target: NA Description: Modified...
BioCentury | Mar 12, 2007
Company News

Nutra Pharma, Zhong Xin Dong Tai Co. Ltd. deal

NPHC's ReceptoPharm Inc. division and Zhong Xin signed a nonbinding letter of intent to create a JV to develop and market NPHC's RPI-MN antiviral compound in China. Zhong Xin's Nanogene Biotechnology Co. Ltd. subsidiary will...
Items per page:
1 - 10 of 30